TNB-738 is under clinical development by Ancora Biotech and currently in Phase I for Unspecified Immunological Disorders. According to GlobalData, Phase I drugs for Unspecified Immunological Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TNB-738 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TNB-738 overview
TNB-738 is under development for the treatment of autoimmune disorders, unspecified immunological disorders and unspecified metabolic disorders. The drug candidate acts by targeting CD38 enzyme. It is being developed based on UniRat human heavy chain antibody platform.
Ancora Biotech overview
Ancora Biotech is developing drugs for the treatment of cancers, metabolic diseases and chronic infections. The company is headquartered in Palo Alto, California, the US.
For a complete picture of TNB-738’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
